Circulating Mononuclear Cells Nuclear Factor-kappa B Activity, Plasma Xanthine Oxidase, and Low Grade Inflammatory Markers in Adult Patients with Familial Hypercholesterolaemia
Overview
Authors
Affiliations
Background: Few data are available on circulating mononuclear cells nuclear factor-kappa B (NF-kB) activity and plasma xanthine oxidase (XO) activity in heterozygous familial hypercholesterolaemia (FH). The goal of the study was to analyse circulating mononuclear cells NF-kB and plasma XO activities in FH patients.
Materials And Methods: Thirty FH index patients and 30 normoglycaemic normocholesterolaemic controls matched by age, gender, body mass index, abdominal circumference and homeostasis model assessment index were studied. Plasma XO and inflammatory markers were measured by standard methods. NF-kB was assayed in circulating mononuclear cells.
Results: Familial hypercholesterolaemia patients showed a significantly higher NF-kB (75.0 +/- 20.7 vs. 42.7 +/- 16.8 relative luminiscence units) and XO (0.44 +/- 0.13 vs. 0.32 +/- 0.09 mU mL(-1)) activities than controls. In addition, interleukin-1, interleukin-6, high sensitivity C reactive protein (hsCRP) and oxidized LDL (LDL-ox) were also significantly higher in FH patients. In the total group (FH and controls), XO was significantly associated with LDL-cholesterol (LDL-C), apolipoprotein B (apoB), NF-kB and hsCPR, and NF-kB activity was significantly associated with XO, hsCPR, LDL-ox, LDL-C and apoB plasma values. Using multiple regression analysis, XO was independently associated with hsCPR and NF-kB, and NF-kB activity in circulating mononuclear cells was independently associated with apoB and LDL-ox plasma values.
Conclusion: Familial hypercholesterolaemia patients show increased activities of NF-kB and XO, and higher values of low grade inflammatory markers related to atherosclerosis. NF-kB activity was independently associated with apoB plasma values. These data could explain in part the high cardiovascular disease risk present in these patients.
Mechanism of Hypercholesterolemia-Induced Atherosclerosis.
Prasad K, Mishra M Rev Cardiovasc Med. 2024; 23(6):212.
PMID: 39077184 PMC: 11273781. DOI: 10.31083/j.rcm2306212.
Tryfonos A, Mills J, Green D, Wagenmakers A, Dawson E, Cocks M Eur J Appl Physiol. 2022; 123(2):367-380.
PMID: 36305972 PMC: 9894982. DOI: 10.1007/s00421-022-05040-z.
Wu Y, Lu Y, Ren D, Chen X, Yang X J Food Drug Anal. 2022; 29(1):87-97.
PMID: 35696221 PMC: 9261843. DOI: 10.38212/2224-6614.3078.
Chen T, Ding X, Tang W, Chen L, Mao D, Song L BMJ Open. 2022; 12(4):e056143.
PMID: 35365527 PMC: 8977806. DOI: 10.1136/bmjopen-2021-056143.
Alternative C3 Complement System: Lipids and Atherosclerosis.
Garcia-Arguinzonis M, Diaz-Riera E, Pena E, Escate R, Juan-Babot O, Mata P Int J Mol Sci. 2021; 22(10).
PMID: 34066088 PMC: 8151937. DOI: 10.3390/ijms22105122.